G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Dr. Mensen adds that tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP agonist, may also be recommended. "Based on the fact that each individual experience with this medication is different ...

while its dual GLP-1/GIP agonist tirzepatide was approved for diabetes in May and for obesity just last week. Outside China, the tirzepatide products are known as Mounjaro and Zepbound ...

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.